Once people realize that it is the secondary endpoint(s) that really matter in our mild to moderate clinical trial , and not the primary endpoint, then our stock should really take off. After all, if the placebo patients have say 85 to 95% clinical improvement by day 14, then no drug in the world can ever beat that by a statistically significant number. The FDA and the smart investors will understand this. I am thrilled with our results!